Literature DB >> 32139386

Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study.

Sari Mäkimattila1, Valma Harjutsalo2,3,4,5, Carol Forsblom2,3,4, Per-Henrik Groop.   

Abstract

OBJECTIVE: The aim of this study was to quantify the excess risk of autoimmune hypothyroidism and hyperthyroidism, Addison disease, celiac disease, and atrophic gastritis in adults with type 1 diabetes (T1D) compared with nondiabetic individuals in Finland. RESEARCH DESIGN AND METHODS: The study included 4,758 individuals with T1D from the Finnish Diabetic Nephropathy (FinnDiane) Study and 12,710 nondiabetic control individuals. The autoimmune diseases (ADs) were identified by linking the data with the Finnish nationwide health registries from 1970 to 2015.
RESULTS: The median age of the FinnDiane individuals at the end of follow-up in 2015 was 51.4 (interquartile range 42.6-60.1) years, and the median duration of diabetes was 35.5 (26.5-44.0) years. Of individuals with T1D, 22.8% had at least one additional AD, which included 31.6% of women and 14.9% of men. The odds ratios for hypothyroidism, hyperthyroidism, celiac disease, Addison disease, and atrophic gastritis were 3.43 (95% CI 3.09-3.81), 2.98 (2.27-3.90), 4.64 (3.71-5.81), 24.13 (5.60-104.03), and 5.08 (3.15-8.18), respectively, in the individuals with T1D compared with the control individuals. The corresponding ORs for women compared with men were 2.96 (2.53-3.47), 2.83 (1.87-4.28), 1.52 (1.15-2.02), 2.22 (0.83-5.91), and 1.36 (0.77-2.39), respectively, in individuals with T1D. Late onset of T1D and aging increased the risk of hypothyroidism, whereas young age at onset of T1D increased the risk of celiac disease.
CONCLUSIONS: This is one of the largest studies quantifying the risk of coexisting AD in adult individuals with T1D in the country with the highest incidence of T1D in the world. The results highlight the importance of continuous screening for other ADs in individuals with T1D.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID: 32139386     DOI: 10.2337/dc19-2429

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease.

Authors:  Sara Bruzzaniti; Erica Piemonte; Enza Mozzillo; Dario Bruzzese; Maria Teresa Lepore; Fortunata Carbone; Paola de Candia; Rocky Strollo; Antonio Porcellini; Marco Marigliano; Claudio Maffeis; Maurizio Bifulco; Johnny Ludvigsson; Adriana Franzese; Giuseppe Matarese; Mario Galgani
Journal:  Diabetologia       Date:  2022-05-25       Impact factor: 10.460

2.  Gene Expression Signatures Reveal Common Virus Infection Pathways in Target Tissues of Type 1 Diabetes, Hashimoto's Thyroiditis, and Celiac Disease.

Authors:  Min Yin; Yan Zhang; Shanshan Liu; Juan Huang; Xia Li
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

3.  Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.

Authors:  Saara Kuusisalo; Jussi P Koivunen; Sanna Iivanainen
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

Review 4.  Type 1 diabetes mellitus: much progress, many opportunities.

Authors:  Alvin C Powers
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

5.  Comment on Mäkimattila et al. Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study. Diabetes Care 2020;43:1041-1047.

Authors:  Giuseppe Bellastella; Maria Ida Maiorino; Katherine Esposito
Journal:  Diabetes Care       Date:  2020-08       Impact factor: 19.112

6.  Unravelling the Shared Genetic Mechanisms Underlying 18 Autoimmune Diseases Using a Systems Approach.

Authors:  Sreemol Gokuladhas; William Schierding; Evgeniia Golovina; Tayaza Fadason; Justin O'Sullivan
Journal:  Front Immunol       Date:  2021-08-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.